J. Timothy Meigs

Sector Patent Counsel

Genetic Therapy, Inc. 9 West Watkins Mill Road Gaithersburg, MD 20878

Tel (301) 258-4715 Fax (301) 258-4620 Email: tim.meigs@pharma.novartis.com

Fax

**FAX RECEIVED** 

AUG 0 9 2002

Attention

Examiner Bronwen Loeb, PTO Art Unit 1636

Fax no.

(703) 308-4242

GROUP 1600

OFFICIAL

Number of pages

21

Date

August 9, 2002

RE: 09/715,249

Dear Examiner Loeb,

Attached hereto for filing in 09/715,249 are a Reply Under 37 CFR §1.111 With Amendment including a petition for a three month extension of time and a Fee Transmittal Sheet.

Respectfully submitted,

Reg. No. 38,241

Attorney for Applicant

PRIVILEGED AND CONFIDENTIAL information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original to us at the address above via the U.S. Mail. Thank you.



+3012584620

I hereby certify that this paper is being facsimile transmitted to the Patent Office Fax No. (703) 308-4242 on the date shown below.

CERTIFICATE OF FACSIMILE TRANSMISSION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pippig et al. Confirmation No. 7928

App. No. 09/715,249 Art Unit: 1636

Filed: November 17, 2000 Examiner: Bronwen Loeb

For: Selectable Cell Surface Marker Genes Atty Docket: 4-31192A

## REPLY UNDER 37 CFR § 1.111 WITH AMENDMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action dated February 9, 2002, please enter the amendments set forth below consider the following remarks.

An Extension of Time for three months is hereby requested pursuant to 37 C.F.R. §1.136(a). Please charge Deposit Account No. 19-0134 (in the name of Novartis Pharmaceutical Corporation) in the amount of \$920.00 for payment of the extension fee. The Commissioner is authorized to charge any additional fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Novartis Pharmaceutical Corporation's Deposit Addicate Novartis Pharmaceutical Corporation's Deposit Addicates Novartis Pharmaceutical Corporation (Novartis Pharmaceutical Corporation) (Novartis Pharmaceutical Co 09715249

> 01 FC:117 920.00 CH

02 FC:103 198.00 CH

03 FC:102 84.00 CH